Ogino S, Kubo S, Abdul-Karim F W, Cohen M L
Department of Pathology, University Hospitals of Cleveland and Case Western Reserve University, OH 44106, USA.
Pediatr Dev Pathol. 2001 Jan-Feb;4(1):23-31. doi: 10.1007/s100240010112.
Insulin-like growth factor (IGF)-II is an important growth factor in development of the central nervous system. The purpose of this study was to evaluate expression of IGF-II and IGF receptor type 1 (IGFR1) in various pediatric brain tumors. Immunohistochemistry for IGF-II and IGFR1 was performed on 15 choroid plexus papillomas (CPPs) including 1 atypical CPP, 2 choroid plexus carcinomas (CPCs), 5 anaplastic ependymomas, 7 nonanaplastic ependymomas (simply referred to as "ependymoma"), 5 medulloblastomas, 1 cerebral neuroblastoma, and 1 atypical teratoid/rhabdoid tumor (ATRT) along with 10 non-neoplastic choroid plexus and 3 non-neoplastic ependymal linings. All non-neoplastic choroid plexus, CPPs, CPCs, anaplastic ependymomas, ATRT, 71% of ependymomas, and 67% of non-neoplastic ependymal linings showed cytoplasmic positivity for IGF-II, whereas all medulloblastomas and the cerebral neuroblastoma were negative for IGF-II. In addition to cytoplasmic positivity for IGFR1, membranous positivity was observed in 73% of CPPs, both CPCs, the ATRT, 22% of non-neoplastic choroid plexus, 80% of anaplastic ependymomas, and 29% of ependymomas, but not in any medulloblastoma, cerebral neuroblastoma, or non-neoplastic ependymal lining. IGF-II and IGFR1 may play roles in the pathogeneses of CPP, CPC, anaplastic ependymoma, ependymoma, and ATRT. Immunohistochemical testing for IGF-II and IGFR1 may be useful in differentiating ATRT, CPC, and anaplastic ependymoma from medulloblastoma and cerebral neuroblastoma.
胰岛素样生长因子(IGF)-II是中枢神经系统发育中的一种重要生长因子。本研究的目的是评估IGF-II和1型IGF受体(IGFR1)在各种小儿脑肿瘤中的表达情况。对15例脉络丛乳头状瘤(CPP)(包括1例非典型CPP)、2例脉络丛癌(CPC)、5例间变性室管膜瘤、7例非间变性室管膜瘤(简称为“室管膜瘤”)、5例髓母细胞瘤、1例脑神经母细胞瘤和1例非典型畸胎样/横纹肌样肿瘤(ATRT)以及10例非肿瘤性脉络丛和3例非肿瘤性室管膜衬里进行了IGF-II和IGFR1的免疫组织化学检测。所有非肿瘤性脉络丛、CPP、CPC、间变性室管膜瘤、ATRT、71%的室管膜瘤以及67%的非肿瘤性室管膜衬里均显示IGF-II的细胞质阳性,而所有髓母细胞瘤和脑神经母细胞瘤的IGF-II均为阴性。除了IGFR1的细胞质阳性外,在73%的CPP、2例CPC、ATRT、22%的非肿瘤性脉络丛、80%的间变性室管膜瘤和29%的室管膜瘤中观察到膜性阳性,但在任何髓母细胞瘤、脑神经母细胞瘤或非肿瘤性室管膜衬里中均未观察到。IGF-II和IGFR1可能在CPP、CPC、间变性室管膜瘤、室管膜瘤和ATRT的发病机制中起作用。IGF-II和IGFR1的免疫组织化学检测可能有助于将ATRT、CPC和间变性室管膜瘤与髓母细胞瘤和脑神经母细胞瘤区分开来。